abstract |
The invention concerns quinazoline derivatives of the formula I <IMAGE> I wherein n is 1,2 or 3 and each R2 is independently halogeno, trifluoromethyl or (1-4C)alkyl; R1 is (1-4C)alkoxy; A is (1-4C)alkylene; and Q is a saturated, monocyclic 4-, 5-, 6- or 7-membered heterocyclic ring containing one or two oxygen heteroatoms, which ring optionally bears up to four (1-4C)alkyl substituents; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and the use of their receptor tyrosine kinase inhibitory properties in the treatment of proliferative disease such as cancer. |